New cell shot aims to tame stubborn nerve attacks
Disease control
Not yet recruiting
This early-stage study tests a new cell treatment called HY001N for people with severe autoimmune diseases that attack the brain, spinal cord, or nerves and have not responded to standard therapies. The main goal is to check if the treatment is safe and tolerable in 15 adults age…
Phase: EARLY_PHASE1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC